Cargando…
Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy
BACKGROUND: A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advanc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133945/ https://www.ncbi.nlm.nih.gov/pubmed/29961756 http://dx.doi.org/10.1038/s41416-018-0149-z |
_version_ | 1783354576916709376 |
---|---|
author | Huis in ’t Veld, Eva A. Grünhagen, Dirk J. Deroose, Jan P. Nijsten, Tamar E. C. Wouters, Michel W. J. M. Verhoef, Cornelis van Houdt, Winan J. Hayes, Andrew J. |
author_facet | Huis in ’t Veld, Eva A. Grünhagen, Dirk J. Deroose, Jan P. Nijsten, Tamar E. C. Wouters, Michel W. J. M. Verhoef, Cornelis van Houdt, Winan J. Hayes, Andrew J. |
author_sort | Huis in ’t Veld, Eva A. |
collection | PubMed |
description | BACKGROUND: A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advanced extremity cSCC. METHODS: A retrospective search from prospectively maintained databases, at two tertiary referral centers, was performed to identify patients treated with TM-ILP for locally advanced cSSC of an extremity between 2000 and 2015. RESULTS: A total of 30 patients treated with TM-ILP for cSCC were identified, with a median age of 71 years (36–92) and 50% female. Response could not be evaluated in 3 patients. After a median follow up of 25 months, the overall response rate was 81% (n = 22), with 16 patients having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with a median time to recurrence of 9 months (Interquartile Range 7–10). Progressive disease was observed in 5 patients (19%). Limb salvage rate was 80%. The overall 2-year survival was 67%. CONCLUSIONS: TM-ILP should be considered as an option in patients with locally advanced cSCC in specialised centers, resulting in a high limb salvage rate. |
format | Online Article Text |
id | pubmed-6133945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61339452019-08-14 Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy Huis in ’t Veld, Eva A. Grünhagen, Dirk J. Deroose, Jan P. Nijsten, Tamar E. C. Wouters, Michel W. J. M. Verhoef, Cornelis van Houdt, Winan J. Hayes, Andrew J. Br J Cancer Article BACKGROUND: A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advanced extremity cSCC. METHODS: A retrospective search from prospectively maintained databases, at two tertiary referral centers, was performed to identify patients treated with TM-ILP for locally advanced cSSC of an extremity between 2000 and 2015. RESULTS: A total of 30 patients treated with TM-ILP for cSCC were identified, with a median age of 71 years (36–92) and 50% female. Response could not be evaluated in 3 patients. After a median follow up of 25 months, the overall response rate was 81% (n = 22), with 16 patients having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with a median time to recurrence of 9 months (Interquartile Range 7–10). Progressive disease was observed in 5 patients (19%). Limb salvage rate was 80%. The overall 2-year survival was 67%. CONCLUSIONS: TM-ILP should be considered as an option in patients with locally advanced cSCC in specialised centers, resulting in a high limb salvage rate. Nature Publishing Group UK 2018-07-02 2018-08-14 /pmc/articles/PMC6133945/ /pubmed/29961756 http://dx.doi.org/10.1038/s41416-018-0149-z Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Article Huis in ’t Veld, Eva A. Grünhagen, Dirk J. Deroose, Jan P. Nijsten, Tamar E. C. Wouters, Michel W. J. M. Verhoef, Cornelis van Houdt, Winan J. Hayes, Andrew J. Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy |
title | Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy |
title_full | Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy |
title_fullStr | Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy |
title_full_unstemmed | Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy |
title_short | Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy |
title_sort | isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133945/ https://www.ncbi.nlm.nih.gov/pubmed/29961756 http://dx.doi.org/10.1038/s41416-018-0149-z |
work_keys_str_mv | AT huisintveldevaa isolatedlimbperfusionforunresectableextremitycutaneoussquamouscellcarcinomaaneffectivelimbsavingstrategy AT grunhagendirkj isolatedlimbperfusionforunresectableextremitycutaneoussquamouscellcarcinomaaneffectivelimbsavingstrategy AT deroosejanp isolatedlimbperfusionforunresectableextremitycutaneoussquamouscellcarcinomaaneffectivelimbsavingstrategy AT nijstentamarec isolatedlimbperfusionforunresectableextremitycutaneoussquamouscellcarcinomaaneffectivelimbsavingstrategy AT woutersmichelwjm isolatedlimbperfusionforunresectableextremitycutaneoussquamouscellcarcinomaaneffectivelimbsavingstrategy AT verhoefcornelis isolatedlimbperfusionforunresectableextremitycutaneoussquamouscellcarcinomaaneffectivelimbsavingstrategy AT vanhoudtwinanj isolatedlimbperfusionforunresectableextremitycutaneoussquamouscellcarcinomaaneffectivelimbsavingstrategy AT hayesandrewj isolatedlimbperfusionforunresectableextremitycutaneoussquamouscellcarcinomaaneffectivelimbsavingstrategy |